Cor Vasa 2021, 63(6):668-673 | DOI: 10.33678/cor.2021.062

Prognostic implication of uncontrolled hypertension in hospitalized patients with COVID-19

İbrahim Halil Özdemira, Bülent Özlekb, Mehmet Burak Özena, Ramazan Gündüza, Nurullah Çetinc
a Department of Cardiology, Manisa City Hospital, Manisa, Turkey
b Department of Cardiology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey
c Department of Cardiology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey

Objective: In this study, we aimed to investigate the effect of hypertension (HT) and antihypertensive treatment on prognosis, which is one of the cardiovascular risk factors affecting the prognosis of COVID-19.

Methods: We included 117 patients diagnosed with COVID-19 by nasopharyngeal polymerase chain reaction (PCR). The patients were divided into a hypertensive group and a control group. Biochemical, complete blood count and imaging data of the patients were recorded. Mortality of patients with and without HT was evaluated. The effect of antihypertensive therapy on mortality was evaluated.

Results: In thorax CT, ground glass opacity and pneumonic consolidation were found statistically significantly higher in the hypertensive group (p <0,001). Hospital stay duration (days) of the patients were significantly longer in the hypertensive group and need for intensive care unit was statistically higher in the hypertensive group (p <0,001). Mortality of hypertensive patients was higher than of those without hypertension (p <0,001). There was no statistically significant difference in mortality in antihypertensive treatment groups (p = 0,801).

Conclusion: Hypertension is an important risk factor that increases mortality in COVID-19 patients. Uncontrolled hypertension was common in most patients. Inflammatory parameters are higher especially in patients with uncontrolled hypertension. Patients with uncontrolled hypertension have a higher risk of mortality. There is no data to suggesting that the use of ACEI/ARB worsens prognosis. High blood pressure on admission to the hospital is important and the patient's current antihypertensive therapy should not be discontinued.

Keywords: Antihypertensive treatment, Blood pressure, COVID-19, Hypertension

Received: April 28, 2021; Revised: May 18, 2021; Accepted: May 20, 2021; Published: December 13, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Özdemir İH, Özlek B, Burak Özen M, Gündüz R, Çetin N. Prognostic implication of uncontrolled hypertension in hospitalized patients with COVID-19. Cor Vasa. 2021;63(6):668-673. doi: 10.33678/cor.2021.062.
Download citation

References

  1. Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect 2020;9:313-319. Go to original source... Go to PubMed...
  2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-733. Go to original source... Go to PubMed...
  3. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. BMJ (Clinical research ed) 2020;368:m1036. Go to original source... Go to PubMed...
  4. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-118. Go to original source... Go to PubMed...
  5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020;395:497-506. Go to original source... Go to PubMed...
  6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 2020;395:507-513. Go to original source... Go to PubMed...
  7. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J 2020;133:1025-1031. Go to original source... Go to PubMed...
  8. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181:271-280.e8. Go to original source... Go to PubMed...
  9. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-1720. Go to original source... Go to PubMed...
  10. Lee KS. Pneumonia Associated with 2019 Novel Coronavirus: Can Computed Tomographic Findings Help Predict the Prognosis of the Disease? Korean J Radiol 2020;21:257-258. Go to original source... Go to PubMed...
  11. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844-847. Go to original source... Go to PubMed...
  12. Matsumoto H, Kasai T, Sato A, et al. Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. Heart Vessels 2019;34:1961-1968. Go to original source... Go to PubMed...
  13. Bilgir O, Bilgir F, Calan M, et al. Comparison of pre- and post-levothyroxine high-sensitivity c-reactive protein and fetuin-a levels in subclinical hypothyroidism. Clinics (Sao Paulo) 2015;70:97-101. Go to original source... Go to PubMed...
  14. Faria SS, Fernandes Jr PC, Silva MJB, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience 2016;10:702. Go to original source... Go to PubMed...
  15. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan. Clin Infect Dis. 2020 Mar 12 : ciaa248. Published online 2020 Mar 12. doi: 10.1093/cid/ciaa248 Go to original source... Go to PubMed...
  16. Alfaraj SH, Al-Tawfiq JA, Assiri AY, et al. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel Med Infect Dis 2019;29:48-50. Go to original source... Go to PubMed...
  17. Leist SR, Jensen KL, Baric RS, Sheahan TP. Increasing the translation of mouse models of MERS coronavirus pathogenesis through kinetic hematological analysis. PLoS One 2019;14:e0220126. Go to original source... Go to PubMed...
  18. Magen E, Mishal J, Paskin J, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J Clin Hypertens (Greenwich) 2008;10:677-683. Go to original source... Go to PubMed...
  19. Hosford-Donovan A, Nilsson A, Wåhlin-Larsson B, Kadi F. Observational and mechanistic links between C-reactive protein and blood pressure in elderly women. Maturitas 2016;89:52-57. Go to original source... Go to PubMed...
  20. Perticone F, Maio R, Perticone M, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010;122:379-384. Go to original source... Go to PubMed...
  21. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003;17:223-230. Go to original source... Go to PubMed...
  22. Amar J, Touront N, Ciron AM, Pendaries C. Interactions between hypertension and inflammatory tone and the effect on blood pressure and outcomes in patients with COVID-19. J Clin Hypertens (Greenwich) 2021;23:238-244. Go to original source... Go to PubMed...
  23. Sardu C, Gambardella J, Morelli MB, et al. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med 2020;9:1417. Go to original source... Go to PubMed...
  24. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-1062. Go to original source... Go to PubMed...
  25. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21. Go to original source... Go to PubMed...
  26. Wang Y, Chen B, Li Y, et al. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis. J Med Virol 2021;93:1370-1377. Go to original source... Go to PubMed...
  27. Desai A, Voza G, Paiardi S, et al. The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. Int J Cardiol 2021;324:249-254. Go to original source... Go to PubMed...
  28. Caldeira D, Alves M, Gouveia E Melo R, et al. Angiotensin--converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. Int J Cardiol Heart Vasc 2020;31:100627. Go to original source... Go to PubMed...
  29. Hasan SS, Kow CS, Hadi MA, et al. Mortality and Disease severity. Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta- -analysis. Am J Cardiovasc Drugs 2020;20:571-590. Go to original source... Go to PubMed...
  30. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular pharmacology. Vascul Pharmacol 2020;135:106805. Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.